NAD+Longevity

Overview

Nicotinamide adenine dinucleotide (NAD+) is not a peptide but an endogenous coenzyme present in every cell, sitting at the center of energy metabolism. It cycles between oxidized (NAD+) and reduced (NADH) forms to carry electrons through ATP-generating reactions, and it is consumed as a substrate by sirtuins, PARPs and CD38 that govern DNA repair and stress responses. Because tissue NAD+ falls with age, NAD+ and its precursors are marketed for "anti-aging," energy and recovery — as IV infusions (NAD+ itself) and oral supplements (the precursors NR and NMN). It is a research-grade compound, not FDA-approved, and its marketed human benefits are largely unproven.

Mechanism

NAD+ works two ways. As a redox cofactor it shuttles electrons in glycolysis, the citric-acid cycle and oxidative phosphorylation, coupling it directly to mitochondrial ATP output. Separately it is the obligatory substrate for NAD+-consuming enzymes: sirtuins (protein deacetylation), PARPs (DNA-damage repair) and CD38 (immune/calcium signaling). It therefore acts as a coenzyme and enzyme substrate, not a cell-surface-receptor ligand. Because intact NAD+ is poorly cell-permeable, oral supplementation relies on precursors that cells convert back into NAD+.

Clinical evidence

The strongest human data are for precursors, not NAD+ itself. A randomized placebo-controlled crossover trial found oral nicotinamide riboside (1,000 mg/day) was well tolerated and reliably raised the NAD+ metabolome, with only preliminary signals on blood pressure (Martens 2018). A 12-week RCT of nicotinamide mononucleotide likewise raised NAD+ metabolism but produced only a non-significant trend on arterial stiffness (Katayoshi 2023) — NAD+ went up, but clear clinical benefit did not follow. Direct IV NAD+ has only pilot data: a 6-hour infusion study found plasma NAD+ barely moved for the first two hours, underscoring how little rigorous human evidence exists for the IV route (Grant 2019). Anti-aging/energy benefits are not established by controlled trials.

Safety profile

NAD+ is endogenous, and oral precursors (NR/NMN) have a reassuring short-term safety record in RCTs, generally well tolerated to ~1,000 mg/day with occasional mild GI upset or flushing. The main acute issue is rapid IV NAD+, which commonly provokes flushing, nausea, chest/abdominal tightness and lightheadedness — mitigated by slowing the infusion. Long-term, high-dose safety data are limited and product quality in the unregulated market varies. NAD+/NR/NMN are not named on the WADA list, but WADA's general ban on IV infusions >100 mL per 12 h can apply to NAD+ drips regardless of the molecule. Research-use only; not a treatment for any condition.

Compare

• vs MOTS-c

  Both are promoted for mitochondrial/metabolic and energy benefits, but MOTS-c is a mitochondrial-derived peptide acting via signaling, whereas NAD+ is a redox coenzyme and enzyme substrate.

• vs 5-Amino-1MQ

  5-Amino-1MQ is investigated to raise NAD+ indirectly by inhibiting NNMT (sparing the precursor NMN), a complementary metabolic angle to supplying NAD+ or its precursors directly.

• vs Glutathione

  Both are endogenous non-peptide metabolites marketed for IV wellness; glutathione is a thiol antioxidant for redox detox, while NAD+ is a redox coenzyme central to energy metabolism.